Cerity Partners OCIO’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $4.35M | Buy |
39,245
+2,181
| +6% | +$223K | 0.14% | 100 |
|
|
2022
Q3 | $3.19M | Buy |
37,064
+2,156
| +6% | +$192K | 0.11% | 106 |
|
|
2022
Q2 | $3.18M | Buy |
34,908
+5,069
| +17% | +$449K | 0.11% | 106 |
|
|
2022
Q1 | $2.45M | Buy |
29,839
+4,028
| +16% | +$318K | 0.07% | 130 |
|
|
2021
Q4 | $1.98M | Buy |
25,811
+1,269
| +5% | +$101K | 0.06% | 152 |
|
|
2021
Q3 | $1.84M | Sell |
24,542
-42,201
| -63% | -$3.21M | 0.06% | 137 |
|
|
2021
Q2 | $5.19M | Buy |
66,743
+44,133
| +195% | +$3.28M | 0.17% | 67 |
|
|
2021
Q1 | $1.66M | Sell |
22,610
-2,599
| -10% | -$192K | 0.06% | 129 |
|
|
2020
Q4 | $1.97M | Buy |
25,209
+173
| +0.7% | +$13.2K | 0.08% | 116 |
|
|
2020
Q3 | $1.98M | Buy |
25,036
+2,028
| +9% | +$159K | 0.09% | 102 |
|
|
2020
Q2 | $1.7M | Sell |
23,008
-193
| -0.8% | -$14.5K | 0.08% | 118 |
|
|
2020
Q1 | $1.7M | Buy |
23,201
+1,235
| +6% | +$97.1K | 0.1% | 97 |
|
|
2019
Q4 | $1.78M | Buy |
21,966
+6,442
| +41% | +$529K | 0.08% | 106 |
|
|
2019
Q3 | $1.25M | Buy |
15,524
+996
| +7% | +$79.8K | 0.06% | 124 |
|
|
2019
Q2 | $1.16M | Sell |
14,528
-653
| -4% | -$50K | 0.06% | 122 |
|
|
2019
Q1 | $1.21M | Sell |
15,181
-16,689
| -52% | -$1.25M | 0.07% | 116 |
|
|
2018
Q4 | $2.32M | Buy |
31,870
+276
| +0.9% | +$19.5K | 0.15% | 63 |
|
|
2018
Q3 | $2.14M | Sell |
31,594
-20,601
| -39% | -$1.31M | 0.13% | 73 |
|
|
2018
Q2 | $3.02M | Buy |
52,195
+1,389
| +3% | +$78.4K | 0.19% | 49 |
|
|
2018
Q1 | $2.64M | Buy |
50,806
+12,629
| +33% | +$682K | 0.17% | 57 |
|
|
2017
Q4 | $2.05M | Buy |
38,177
+18,698
| +96% | +$1.04M | 0.14% | 65 |
|
|
2017
Q3 | $1.19M | Buy |
19,479
+4,713
| +32% | +$286K | 0.08% | 101 |
|
|
2017
Q2 | $903K | Buy |
14,766
+4,038
| +38% | +$246K | 0.07% | 118 |
|
|
2017
Q1 | $651K | Sell |
10,728
-26,031
| -71% | -$1.58M | 0.05% | 156 |
|
|
2016
Q4 | $2.07M | Buy |
36,759
+4,627
| +14% | +$271K | 0.18% | 53 |
|
|
2016
Q3 | $1.91M | Buy |
32,132
+1,771
| +6% | +$104K | 0.17% | 58 |
|
|
2016
Q2 | $1.66M | Buy |
30,361
+411
| +1% | +$21.9K | 0.17% | 58 |
|
|
2016
Q1 | $1.51M | Buy |
29,950
+3,144
| +12% | +$154K | 0.16% | 66 |
|
|
2015
Q4 | $1.35M | Buy |
26,806
+14,524
| +118% | +$732K | 0.15% | 55 |
|
|
2015
Q3 | $582K | Sell |
12,282
-148
| -1% | -$7.86K | 0.07% | 125 |
|
|
2015
Q2 | $675K | Buy |
12,430
+76
| +0.6% | +$4.26K | 0.07% | 117 |
|
|
2015
Q1 | $678K | Sell |
12,354
-1,027
| -8% | -$58.2K | 0.08% | 112 |
|
|
2014
Q4 | $725K | Buy |
13,381
+678
| +5% | +$37.8K | 0.09% | 99 |
|
|
2014
Q3 | $719K | Buy |
12,703
+4,630
| +57% | +$260K | 0.1% | 84 |
|
|
2014
Q2 | $445K | Sell |
8,073
-974
| -11% | -$53.1K | 0.06% | 113 |
|
|
2014
Q1 | $490K | Sell |
9,047
-1,092
| -11% | -$56.5K | 0.08% | 90 |
|
|
2013
Q4 | $484K | Sell |
10,139
-1,617
| -14% | -$73.9K | 0.08% | 83 |
|
|
2013
Q3 | $534K | Buy |
11,756
+368
| +3% | +$16.8K | 0.1% | 69 |
|
|
2013
Q2 | $505K | Buy |
+11,388
| New | +$509K | 0.1% | 65 |
|
Other funds holding MRK
AWA
Cerity Partners OCIO's MRK Position: Q4 2022 in Review
Cerity Partners OCIO increased its Merck (MRK) stake by 5.9% in Q4 2022, buying an estimated $223K and bringing the position to 39,245 shares worth $4.35M. The position accounts for 0.14% of the portfolio, ranked #100.
Cerity Partners OCIO first reported a position in MRK in Q2 2013 and has held it in 39 quarters since. The position peaked at $5.19M in Q2 2021. 3,234 funds tracked by Wall St. Rank hold MRK as of Q4 2022.
- Cerity Partners OCIO held 39,245 shares of Merck worth $4.35M as of Q4 2022.
- Cerity Partners OCIO bought 2,181 Merck shares in Q4 2022, an estimated $223K.
- Merck made up 0.14% of Cerity Partners OCIO's portfolio in Q4 2022, its #100 holding.
- Cerity Partners OCIO first reported a position in Merck in Q2 2013 and has held it in 39 quarters since.
- Cerity Partners OCIO's Merck position peaked at $5.19M in Q2 2021.
- 3,234 funds tracked by Wall St. Rank held Merck as of Q4 2022.
Based on Cerity Partners OCIO's 13F filing for Q4 2022, filed 2 Feb 2023.